Acute Coronary Syndrome Market Research Report - Forecast to 2027

Acute Coronary Syndrome Market Research Report by Type (Unstable Angina, Nstemi), by Diagnosis (Blood Tests, Imaging, Stress Test), Treatment (Medication, Surgery), End-User (Hospitals & Clinics, Diagnostic Centers) - Forecast Till 2027

ID: MRFR/Pharma/4326-HCR | February 2021 | Region: Global | 100 pages

Acute Coronary Syndrome Market Scenario


Acute Coronary Syndrome market is Expected to grow at an approximate CAGR of 10.4% during the forecast period. The acute coronary syndrome is a medical condition characterized by a sudden slowing or blockage of blood supply to the heart. The acute coronary syndrome can be exampled by myocardial infarction. Indigestion, dyspnea, diaphoresis, and unexplained fatigue are some of the common symptoms associated with the syndrome. The increasing prevalence of coronary heart disease and growing geriatric population is expected to be a major driver for the market growth during the forecast period. According to the Centers for Disease Control and Prevention in 2017, approximately 366,000 people died due to coronary heart disease within the Americas in 2015. Moreover, according to the World Health Organization, people who age 65 years or more are projected to grow from 524 million in 2010 to nearly 1.5 billion by 2050. Additionally, factors such as rising prevalence of diabetes and growing obese population boost the acute coronary syndrome market growth. However, lack of awareness, high therapeutic surgery cost, and low per capita healthcare expenditure in the middle and low-income countries are estimated to restrain the market growth during the forecast period. As per a study published in the Brazilian Journal of Cardiovascular Surgery, the average cost for coronary artery bypass graft surgery, per patient, was estimated to be about USD 7,992.55 in 2017.


Segmentation


The acute coronary syndrome market is segmented on the basis of type, diagnosis, treatment, and end-user.


On the basis of type, the market is segmented into unstable angina, ST-Elevation Myocardial Infarction (STEMI), Non-ST-Elevation Myocardial Infarction (NSTEMI), and others. On the basis of diagnosis, the market is categorized into blood tests, imaging, stress test, and others. The imaging segment is sub-segmented into Myocardial Perfusion Imaging (MPI), Computerized Tomography (CT) angiogram, echocardiogram, coronary angiogram, and others. On the basis of treatment, the market is segmented into medication, surgery, and others. The medication segment is sub-segmented into thrombolytics, nitroglycerin, antiplatelet drugs, beta blockers, statins, surgery, and others. The antiplatelet drugs segment is further segmented into aspirin, clopidogrel, prasugrel, and others. The beta blockers segment is further segmented into metoprolol, nadolol, and others. The statins segment is further segmented into atorvastatin, simvastatin, and others. The surgery segment is sub-segmented into angioplasty and stenting, coronary bypass surgery, and others. On the basis of end-user, the market is segmented into hospitals and clinics, diagnostic centers, academic institutes, and others.


Regional Analysis


The Americas dominates the acute coronary syndrome market owing to the rising prevalence of coronary heart diseases and presence of a well-developed healthcare sector within the region. Moreover, increasing healthcare expenditure and presence of market players within the region boost the market.


Europe stands second in the acute coronary syndrome market due to the increasing availability of funds for research, a huge patient population, and a well-developed healthcare sector. According to the Heart U.K., there were approximately 404,000 hospital admissions due to coronary heart diseases in England during 2012 to 2013. Moreover, growing geriatric and obese population provides favorable backgrounds for market growth within the region.


Asia Pacific is the fastest growing region for the market due to the presence of developing economies such as India, China, Australia, and others within the region. Moreover, a huge patient population, rising healthcare expenditure, and a rapidly developing healthcare sector fuel the market growth.


The Middle East and Africa has the least share in the acute coronary syndrome market. This can be attributed to the low per capita healthcare expenditure and stringent government policies, especially within the African region. On the hand, the Middle East holds a majority of the market due to a well-developed healthcare sector and huge healthcare expenditure.


Key players


The key players for the global acute coronary syndrome market are Boehringer Ingelheim International GmbH (Germany), Johnson & Johnson Services, Inc. (U.S.), Teva Pharmaceutical Industries Ltd. (Israel), Portola Pharmaceuticals, Inc. (U.S.), AbbVie Inc.  (U.S.), AstraZeneca (U.K), Amgen Inc. (U.S.), Bayer AG (Germany), DAIICHI SANKYO COMPANY, LIMITED. (Japan), Eli Lilly and Company (U.S.), GlaxoSmithKline Plc. (U.K), Sanofi (Paris), Novartis AG (Switzerland), Merck & Co., Inc. (U.S.), and others.


Intended Audience



  • Pharmaceutical Companies

  • Biotechnological Institutes

  • Government and Private Laboratories

  • Research and Development (R&D) Companies

  • Medical Research Laboratories

  • Market Research and Consulting Service Providers



Speak to Analyst Ask for Customization

Frequently Asked Questions (FAQ) :


Acute Coronary Syndrome Market is projected to grow at a 10.4 % CAGR between 2020-2027..

The Americas is expected to lead the Acute Coronary Syndrome Market.

Different end users of Acute Coronary Syndrome Market include academic institutes, diagnostic centers, hospitals and clinics, and others.

Growing obese population and rising prevalence of diabetes is adding market growth.

High cost and lack of awareness may limit market growth.

TABLE OF CONTENT

Chapter 1. Report Prologue

Chapter 2. Market Introduction

2.1 Definition

2.2 Scope of the Study

2.2.1 Research Objective

2.2.2 Assumptions

2.2.3 Limitations

Chapter 3. Research Methodology

3.1 Introduction

3.2 Primary Research

3.3 Secondary research

3.4 Market Size Estimation

Chapter 4. Market Dynamics

4.1 Drivers

4.2 Restraints

4.3 Opportunities

4.4 Challenges

4.5 Macroeconomic Indicators

4.6 Technology Trends & Assessment

Chapter 5. Market Factor Analysis

5.1 Porter’s Five Forces Analysis

5.1.1 Bargaining Power of Suppliers

5.1.2 Bargaining Power of Buyers

5.1.3 Threat of New Entrants

5.1.4 Threat of Substitutes

5.1.5 Intensity of Rivalry

5.2 Value Chain Analysis

5.3 Investment Feasibility Analysis

5.4 Pricing Analysis

Chapter 6. Global Acute Coronary Syndrome Market, by Type

6.1 Introduction

6.2 Unstable angina

Market Estimates & Forecast, 2020–2027

6.3 ST-Elevation Myocardial Infarction (STEMI)

Market Estimates & Forecast, 2020–2027

6.4 Non-ST-Elevation Myocardial Infarction (NSTEMI)

Market Estimates & Forecast, 2020–2027

Chapter 7. Global Acute Coronary Syndrome Market, by Diagnosis

7.1 Introduction

7.2 Blood Tests

Market Estimates & Forecast, 2020–2027

7.3 Imaging

Market Estimates & Forecast, 2020–2027

7.3.1 Myocardial Perfusion Imaging (MPI)

7.3.2 Computerized Tomography (CT) Angiogram

7.3.3 Echocardiogram

7.3.4 Coronary Angiogram

7.3.5 Others

7.4 Stress Test

7.5 Others

Chapter 8. Global Acute Coronary Syndrome Market, by Treatment

8.1 Introduction

8.2 Medication

Market Estimates & Forecast, 2020–2027

8.2.1 Thrombolytics

Market Estimates & Forecast, 2020–2027

8.2.2 Nitroglycerin

Market Estimates & Forecast, 2020–2027

8.2.3 Antiplatelet Drugs

Market Estimates & Forecast, 2020–2027

8.2.3.1 Aspirin

8.2.3.2 Clopidogrel

8.2.3.3 Prasugrel

8.2.3.4 Others

8.2.4 Beta Blockers

Market Estimates & Forecast, 2020–2027

8.2.4.1 Metoprolol

8.2.4.2 Nadolol

8.2.4.3 Others

8.2.5 Statins

Market Estimates & Forecast, 2020–2027

8.2.5.1 Atorvastatin

8.2.5.2 Simvastatin

8.2.5.3 Others

8.2.6 Others

8.3 Surgery

Market Estimates & Forecast, 2020–2027

8.3.1 Angioplasty & Stenting

8.3.2 Coronary Bypass Surgery

8.3.3 Others

Chapter 9. Global Acute Coronary Syndrome Market, by End-User

9.1 Introduction

9.2 Hospital & Clinics

Market Estimates & Forecast, 2020–2027

9.3 Diagnostic Centers

Market Estimates & Forecast, 2020–2027

9.4 Academic Institutes

Market Estimates & Forecast, 2020–2027

9.5 Others

Chapter 10. Global Acute Coronary Syndrome Market, by Region

10.1 Introduction

10.2 America

10.2.1 North America

10.2.1.1 U.S.

10.2.1.2 Canada

10.2.2 South America

10.3 Europe

10.3.1 Western Europe

10.3.1.1 Germany

10.3.1.2 France

10.3.1.3 Italy

10.3.1.4 Spain

10.3.1.5 U.K.

10.3.1.6 Rest of Western Europe

10.3.2 Eastern Europe

10.4 Asia Pacific

10.4.1 Japan

10.4.2 China

10.4.3 India

10.4.4 Australia

10.4.5 Republic of Korea

10.4.6 Rest of Asia Pacific

10.5 The Middle East & Africa

10.5.1 United Arab Emirates

10.5.2 Saudi Arabia

10.5.3 Oman

10.5.4 Kuwait

10.5.5 Qatar

10.5.6 Rest of the Middle East & Africa

Chapter 11. Company Landscape

11.1 Introduction

11.2 Market Share Analysis

11.3 Key Development & Strategies

11.3.1 Key Developments

Chapter 12 Company Profiles

12.1 Boehringer Ingelheim International GmbH

12.1.1 Company Overview

12.1.2 Type Overview

12.1.3 Financials

12.2.4 Key Developments

12.1.5 SWOT Analysis

12.2 Johnson & Johnson Services, Inc.

12.2.1 Company Overview

12.2.2 Type Overview

12.2.3 Financial Overview

12.2.4 Key Developments

12.2.5 SWOT Analysis

12.3 Teva Pharmaceutical Industries Ltd.

12.3.1 Company Overview

12.3.2 Type Overview

12.3.3 Financial Overview

12.3.4 Key Development

12.3.5 SWOT Analysis

12.4 Portola Pharmaceuticals, Inc.

12.4.1 Company Overview

12.4.2 Type/Business Segment Overview

12.4.3 Financial Overview

12.4.4 Key Development

12.4.5 SWOT Analysis

12.5 AbbVie Inc.

12.5.1 Company Overview

12.5.2 Type Overview

12.5.3 Financial overview

12.5.4 Key Developments

12.5.5 SWOT Analysis

12.6 AstraZeneca

12.6.1 Company Overview

12.6.2 Type Overview

12.6.3 Financial Overview

12.6.4 Key Developments

12.6.5 SWOT Analysis

12.7 Amgen Inc.

12.7.1 Overview

12.7.2 Type Overview

12.7.3 Financials

12.7.4 Key Developments

12.7.5 SWOT Analysis

12.8 Bayer AG

12.8.1 Overview

12.8.2 Type Overview

12.8.3 Financials

12.8.4 Key Developments

12.8.5 SWOT Analysis

12.9 DAIICHI SANKYO COMPANY, LIMITED.

12.9.1 Overview

12.9.2 Type Overview

12.9.3 Financials

12.9.4 Key Developments

12.9.5 SWOT Analysis

12.10 Eli Lilly and Company

12.10.1 Overview

12.10.2 Type Overview

12.10.3 Financials

12.10.4 Key Developments

12.10.5 SWOT Analysis

12.11 GlaxoSmithKline Plc.

12.11.1 Overview

12.11.2 Type Overview

12.11.3 Financials

12.11.4 Key Developments

12.11.5 SWOT Analysis

12.12 Sanofi

12.12.1 Overview

12.12.2 Type Overview

12.12.3 Financials

12.12.4 Key Developments

12.12.5 SWOT Analysis

12.13 Novartis AG

12.13.1 Overview

12.13.2 Type Overview

12.13.3 Financials

12.13.4 Key Developments

12.13.5 SWOT Analysis

12.14 Merck & Co., Inc.

12.14.1 Overview

12.14.2 Type Overview

12.14.3 Financials

12.14.4 Key Developments

12.14.5 SWOT Analysis

12.15 Others

Chapter 13 MRFR Conclusion

13.1 Key Findings

13.1.1 From CEO’s View Point

13.1.2 Unmet Needs of the Market

13.2 Key Companies to Watch

13.3 Prediction of Acute Coronary Syndrome Market

Chapter 14 Appendix

LIST OF TABLES

Table 1 Acute Coronary Syndrome Industry Synopsis, 2020–2027

Table 2 Global Acute Coronary Syndrome Market Estimates & Forecast, 2020–2027, (USD Million)

Table 3 Global Acute Coronary Syndrome Market, by Region, 2020–2027, (USD Million)

Table 4 Global Acute Coronary Syndrome Market, by Type, 2020–2027, (USD Million)

Table 5 Global Acute Coronary Syndrome Market, by Diagnosis, 2020–2027, (USD Million)

Table 6 Global Acute Coronary Syndrome Market, by Treatment, 2020–2027, (USD Million)

Table 7 Global Acute Coronary Syndrome Market, by End-User, 2020–2027, (USD Million

Table 8 North America Acute Coronary Syndrome Market, by Type, 2020–2027, (USD Million)

Table 9 North America Acute Coronary Syndrome Market, by Diagnosis, 2020–2027, (USD Million)

Table 10 North America Acute Coronary Syndrome Market, by Treatment, 2020–2027, (USD Million)

Table 11 North America Acute Coronary Syndrome Market, by End-User, 2020–2027, (USD Million)

Table 12 U.S. Acute Coronary Syndrome Market, by Type, 2020–2027, (USD Million)

Table 13 U.S. Acute Coronary Syndrome Market, by Diagnosis, 2020–2027, (USD Million)

Table 14 U.S. Acute Coronary Syndrome Market, by Treatment, 2020–2027, (USD Million)

Table 15 U.S. Acute Coronary Syndrome Market, by End-User, 2020–2027, (USD Million)

Table 16 Canada Acute Coronary Syndrome Market, by Type, 2020–2027, (USD Million)

Table 17 Canada Acute Coronary Syndrome Market, by Diagnosis, 2020–2027, (USD Million)

Table 18 Canada Acute Coronary Syndrome Market, by Treatment, 2020–2027, (USD Million)

Table 19 Canada Acute Coronary Syndrome Market, by End-User, 2020–2027, (USD Million)

Table 20 South America Acute Coronary Syndrome Market, by Type, 2020–2027, (USD Million)

Table 21 South America Acute Coronary Syndrome Market, by Diagnosis, 2020–2027, (USD Million)

Table 22 South America Acute Coronary Syndrome Market, by Treatment, 2020–2027, (USD Million)

Table 23 South America Acute Coronary Syndrome Market, by End-User, 2020–2027, (USD Million)

Table 24 Europe Acute Coronary Syndrome Market, by Type, 2020–2027, (USD Million)

Table 25 Europe Acute Coronary Syndrome Market, by Diagnosis, 2020–2027, (USD Million)

Table 26 Europe Acute Coronary Syndrome Market, by Treatment, 2020–2027, (USD Million)

Table 27 Europe Acute Coronary Syndrome Market, by End-User, 2020–2027, (USD Million)

Table 28 Western Europe Acute Coronary Syndrome Market, by Type, 2020–2027, (USD Million)

Table 29 Western Europe Acute Coronary Syndrome Market, by Diagnosis, 2020–2027, (USD Million)

Table 30 Western Europe Acute Coronary Syndrome Market, by Treatment, 2020–2027, (USD Million)

Table 31 Western Europe Acute Coronary Syndrome Market, by End-User, 2020–2027, (USD Million)

Table 32 Eastern Europe Acute Coronary Syndrome Market, by Type, 2020–2027, (USD Million)

Table 33 Eastern Europe Acute Coronary Syndrome Market, by Diagnosis, 2020–2027, (USD Million)

Table 34 Eastern Europe Acute Coronary Syndrome Market, by Treatment, 2020–2027, (USD Million)

Table 35 Eastern Europe Acute Coronary Syndrome Market, by End-User, 2020–2027, (USD Million)

Table 36 Asia Pacific Acute Coronary Syndrome Market, by Type, 2020–2027, (USD Million)

Table 37 Asia Pacific Acute Coronary Syndrome Market, by Diagnosis, 2020–2027, (USD Million)

Table 38 Asia Pacific Acute Coronary Syndrome Market, by Treatment, 2020–2027, (USD Million)

Table 39 Asia Pacific Acute Coronary Syndrome Market, by End-User, 2020–2027, (USD Million)

Table 40 The Middle East & Africa Acute Coronary Syndrome Market, by Type, 2020–2027, (USD Million)

Table 41 The Middle East & Africa Acute Coronary Syndrome Market, by Diagnosis, 2020–2027, (USD Million)

Table 42 The Middle East & Africa Acute Coronary Syndrome Market, by Treatment, 2020–2027, (USD Million)

Table 43 The Middle East & Africa Acute Coronary Syndrome Market, by End-User, 2020–2027, (USD Million)

LIST OF FIGURES

Figure 1 Research Process

Figure 2 Segmentation for Global Acute Coronary Syndrome Market

Figure 3 Market Dynamics for Global Acute Coronary Syndrome Market

Figure 4 Global Acute Coronary Syndrome Market Share, by Type, 2020

Figure 5 Global Acute Coronary Syndrome Market Share, by Diagnosis, 2020

Figure 6 Global Acute Coronary Syndrome Market Share, by Treatment, 2020

Figure 7 Global Acute Coronary Syndrome Market Share, by End-User, 2020

Figure 8 Global Acute Coronary Syndrome Market Share, by Region, 2020

Figure 9 North America Acute Coronary Syndrome Market Share, by Country, 2020

Figure 10 Europe Acute Coronary Syndrome Market Share, by Country, 2020

Figure 11 Asia Pacific Acute Coronary Syndrome Market Share, by Country, 2020

Figure 12 The Middle East & Africa Acute Coronary Syndrome Market Share, by Country, 2020

Figure 13 Global Acute Coronary Syndrome Market: Company Share Analysis, 2020 (%)

Figure 14 Boehringer Ingelheim International GmbH: Key Financials

Figure 15 Boehringer Ingelheim International GmbH: Segmental Revenue

Figure 16 Boehringer Ingelheim International GmbH: Geographical Revenue

Figure 17 Johnson & Johnson Services, Inc.: Key Financials

Figure 18 Johnson & Johnson Services, Inc.: Segmental Revenue

Figure 19 Johnson & Johnson Services, Inc.: Geographical Revenue

Figure 20 Teva Pharmaceutical Industries Ltd.: Key Financials

Figure 21 Teva Pharmaceutical Industries Ltd.: Segmental Revenue

Figure 22 Teva Pharmaceutical Industries Ltd.: Geographical Revenue

Figure 23 Portola Pharmaceuticals, Inc.: Key Financials

Figure 24 Portola Pharmaceuticals, Inc.: Segmental Revenue

Figure 25 Portola Pharmaceuticals, Inc.: Geographical Revenue

Figure 26 AbbVie Inc.: Key Financials

Figure 27 AbbVie Inc.: Segmental Revenue

Figure 28 AbbVie Inc.: Geographical Revenue

Figure 29 AstraZeneca: Key Financials

Figure 30 AstraZeneca: Segmental Revenue

Figure 31 AstraZeneca: Geographical Revenue

Figure 32 Amgen Inc.: Key Financials

Figure 33 Amgen Inc.: Segmental Revenue

Figure 34 Amgen Inc.: Geographical Revenue

Figure 35 Bayer AG: Key Financials

Figure 36 Bayer AG: Segmental Revenue

Figure 37 Bayer AG: Geographical Revenue

Figure 38 DAIICHI SANKYO COMPANY, LIMITED.: Key Financials

Figure 39 DAIICHI SANKYO COMPANY, LIMITED.: Segmental Revenue

Figure 40 DAIICHI SANKYO COMPANY, LIMITED.: Geographical Revenue

Figure 41 Eli Lilly and Company: Key Financials

Figure 42 Eli Lilly and Company: Segmental Revenue

Figure 43 Eli Lilly and Company: Geographical Revenue

Figure 44 GlaxoSmithKline plc.: Key Financials

Figure 45 GlaxoSmithKline plc.: Segmental Revenue

Figure 46 GlaxoSmithKline plc.: Geographical Revenue

Figure 47 Sanofi: Key Financials

Figure 48 Sanofi: Segmental Revenue

Figure 49 Sanofi: Geographical Revenue

Figure 50 Novartis AG: Key Financials

Figure 51 Novartis AG: Segmental Revenue

Figure 52 Novartis AG: Geographical Revenue

Figure 53 Merck & Co., Inc.: Key Financials

Figure 54 Merck & Co., Inc.: Segmental Revenue

Figure 55 Merck & Co., Inc.: Geographical Revenue